See more : Dustin Group AB (publ) (DUSXF) Income Statement Analysis – Financial Results
Complete financial analysis of Biodexa Pharmaceuticals Plc (BDRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biodexa Pharmaceuticals Plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cadogan Petroleum plc (CAD.L) Income Statement Analysis – Financial Results
- PFSweb, Inc. (PFSW) Income Statement Analysis – Financial Results
- SHF Holdings, Inc. (SHFS) Income Statement Analysis – Financial Results
- Universal Technical Institute, Inc. (UTI) Income Statement Analysis – Financial Results
- Fincantieri S.p.A. (0QWN.L) Income Statement Analysis – Financial Results
Biodexa Pharmaceuticals Plc (BDRX)
About Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 381.00K | 699.00K | 578.00K | 343.00K | 674.00K | 1.94M | 989.00K | 1.32M | 1.38M | 157.00K | 147.00K | 0.00 |
| Cost of Revenue | 4.07M | 5.11M | 4.65M | 6.07M | 7.84M | 9.36M | 8.33M | 7.73M | 70.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.69M | -4.41M | -4.08M | -5.73M | -7.17M | -7.42M | -7.34M | -6.41M | 1.31M | 157.00K | 147.00K | 0.00 |
| Gross Profit Ratio | -967.45% | -631.19% | -705.19% | -1,669.10% | -1,063.65% | -382.92% | -742.16% | -484.28% | 94.91% | 100.00% | 100.00% | 0.00% |
| Research & Development | 4.07M | 5.11M | 4.65M | 16.15M | 7.84M | 9.36M | 9.83M | 7.73M | 8.71M | 5.44M | 2.84M | 1.65M |
| General & Administrative | 4.34M | 4.54M | 2.95M | 4.96M | 3.84M | 4.39M | 4.27M | 3.25M | 2.08M | 4.23M | 1.81M | 2.36M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 6.00K | 323.00K | 0.00 | 170.00K | 0.00 | 605.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 4.34M | 4.54M | 2.95M | 4.96M | 4.16M | 4.39M | 4.44M | 3.25M | 2.69M | 4.23M | 1.81M | 2.36M |
| Other Expenses | -4.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.33M | 4.05M | 1.99M | 17.71M | 3.67M | 4.39M | 5.54M | 2.07M | 12.59M | 9.84M | 4.65M | 4.01M |
| Cost & Expenses | 8.40M | 9.16M | 6.64M | 23.78M | 11.51M | 13.75M | 13.87M | 9.80M | 12.66M | 9.84M | 4.65M | 4.01M |
| Interest Income | 83.00K | 24.00K | 44.00K | 33.00K | 89.00K | 585.00K | 94.00K | 91.00K | 48.00K | 153.00K | 384.00K | 557.00K |
| Interest Expense | 41.00K | 53.00K | 44.00K | 34.00K | 97.00K | 587.00K | 109.00K | 0.00 | 0.00 | 161.00K | 248.00K | 0.00 |
| Depreciation & Amortization | 283.00K | 343.00K | 403.00K | 1.22M | 1.29M | 1.11M | 1.17M | 4.35M | 736.00K | 321.00K | 246.00K | 194.00K |
| EBITDA | -7.16M | -7.40M | -5.66M | -22.22M | -9.54M | -10.70M | -10.61M | -5.30M | -10.49M | -9.36M | -4.25M | -3.81M |
| EBITDA Ratio | -1,879.53% | -1,252.50% | -1,173.88% | -2,790.67% | -1,533.53% | -552.32% | -1,072.70% | -400.76% | -680.44% | -4,709.55% | -2,893.20% | 0.00% |
| Operating Income | -8.01M | -8.93M | -7.00M | -10.67M | -11.32M | -11.82M | -11.78M | -9.65M | -10.09M | -7.72M | -4.50M | -4.01M |
| Operating Income Ratio | -2,103.41% | -1,277.83% | -1,210.73% | -3,111.08% | -1,679.23% | -609.65% | -1,190.70% | -729.55% | -733.96% | -4,914.01% | -3,060.54% | 0.00% |
| Total Other Income/Expenses | 529.00K | 444.00K | 892.00K | -430.00K | 395.00K | -585.00K | -1.19M | 1.26M | 1.69M | -153.00K | -384.00K | -557.00K |
| Income Before Tax | -7.49M | -8.49M | -6.11M | -23.47M | -10.92M | -12.40M | -12.97M | -8.39M | -11.23M | -9.84M | -4.88M | -4.57M |
| Income Before Tax Ratio | -1,964.57% | -1,214.31% | -1,056.40% | -6,842.57% | -1,620.62% | -639.83% | -1,311.43% | -634.01% | -816.87% | -6,267.52% | -3,321.77% | 0.00% |
| Income Tax Expense | -406.00K | 832.00K | 646.00K | 1.28M | 1.79M | 2.03M | 1.27M | 2.23M | 1.13M | 1.02M | 799.00K | 571.00K |
| Net Income | -7.08M | -7.66M | -5.46M | -22.19M | -9.14M | -10.37M | -11.71M | -6.16M | -10.10M | -8.82M | -4.08M | -3.99M |
| Net Income Ratio | -1,858.01% | -1,095.28% | -944.64% | -6,469.10% | -1,355.79% | -534.98% | -1,183.52% | -465.68% | -734.47% | -5,619.11% | -2,778.23% | 0.00% |
| EPS | -224.13 | -619.72 | -542.31 | -4.14K | -3.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -224.13 | -619.72 | -542.31 | -4.14K | -3.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 31.59K | 12.35K | 10.07K | 5.36K | 2.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 31.59K | 12.35K | 10.07K | 5.36K | 2.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at [email protected] or...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK CITY, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at [email protected] or...
Result of General Meeting
November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with...
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ: BDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
Source: https://incomestatements.info
Category: Stock Reports